↓ Skip to main content

Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study)

Overview of attention for article published in European Journal of Haematology, September 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
17 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study)
Published in
European Journal of Haematology, September 2016
DOI 10.1111/ejh.12793
Pubmed ID
Authors

P. Joy Ho, Lay Tay, Juliana Teo, Paula Marlton, Andrew Grigg, Tim St Pierre, Greg Brown, Caro-Anne Badcock, Robert Traficante, Othon L. Gervasio, Donald K. Bowden

Abstract

To assess the effect of iron chelation therapy with deferasirox on cardiac iron and function in patients with transfusion-dependent thalassemia major, sickle-cell disease (SCD) and myelodysplastic syndromes (MDS). This phase IV, single-arm, open-label study over 53 weeks evaluated change in cardiac and liver iron load with deferasirox (up to 40mg/kg/day), measured by magnetic resonance imaging (MRI). Cardiac iron load (myocardial T2*) significantly improved (P=0.002) overall (N=46; n=36 thalassemia major, n=4 SCD, n=6 MDS). Results were significant for patients with normal and moderate baseline cardiac iron (P=0.017 and P=0.015, respectively) but not in the five patients with severe cardiac iron load. Liver iron concentration (LIC) significantly decreased overall (mean LIC 10.4 to 8.2mg Fe/g dry tissue [dw]; P=0.024), particularly in those with baseline LIC >7mg Fe/g dw (19.9 to 15.6mg Fe/g dw; P=0.002). Furthermore, myocardial T2* significantly increased in patients with LIC <7mg Fe/g dw but not in those with a higher LIC. Safety was consistent with previous reports. Once-daily deferasirox over 1year significantly increased myocardial T2* and reduced LIC. This confirms that single-agent deferasirox is effective in the management of cardiac iron, especially for patients with myocardial T2* >10 ms. Clinicaltrials . gov identifier:NCT00673608. This article is protected by copyright. All rights reserved.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 24%
Other 2 12%
Student > Bachelor 2 12%
Student > Doctoral Student 2 12%
Student > Ph. D. Student 2 12%
Other 5 29%
Readers by discipline Count As %
Medicine and Dentistry 6 35%
Psychology 2 12%
Social Sciences 2 12%
Nursing and Health Professions 2 12%
Physics and Astronomy 1 6%
Other 4 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 October 2017.
All research outputs
#7,338,809
of 12,342,865 outputs
Outputs from European Journal of Haematology
#676
of 1,095 outputs
Outputs of similar age
#139,580
of 270,008 outputs
Outputs of similar age from European Journal of Haematology
#9
of 19 outputs
Altmetric has tracked 12,342,865 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,095 research outputs from this source. They receive a mean Attention Score of 2.8. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,008 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.